Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P30518

UPID:
V2R_HUMAN

ALTERNATIVE NAMES:
AVPR V2; Antidiuretic hormone receptor; Renal-type arginine vasopressin receptor

ALTERNATIVE UPACC:
P30518; C5HF20; O43192; Q3MJD3; Q9UCV9

BACKGROUND:
The Vasopressin V2 receptor, identified by UPACC P30518, is integral to the body's ability to regulate water retention. It is recognized by several names including AVPR V2 and Antidiuretic hormone receptor. Its activation by arginine vasopressin through G protein-mediated pathways is essential for the reabsorption of water in the kidneys.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of the Vasopressin V2 receptor could open doors to potential therapeutic strategies. Its involvement in diseases such as Nephrogenic syndrome of inappropriate antidiuresis and X-linked Diabetes insipidus, nephrogenic, 1, highlights its importance in renal water regulation and presents opportunities for targeted drug development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.